Hiring in life sciences? Share your open positions with our professional community. Read more Close

Advertisement

Construction and validation of an interpretable machine learning model for predicting diabetes risk in COPD patients.

Created on 10 Jul 2026

Authors

Lingpin Pang, Siyan Xu, Yingxin Wang, Yiming Liu, Tao Huang, Qian Xian, Wenjia Lin, Haowen Pang, Zhirui Chen, Bozhi Zhong, Hui Miao, Hui Chen, Xishi Sun, Jie Sun, Xiaoting Huang

Published in

Scientific reports. Jul 09, 2026. Epub Jul 09, 2026.

Abstract

To construct and validate a machine learning (ML) model for predicting diabetes risk in COPD patients, enabling early and personalized intervention. Using data from the MIMIC-IV database, 49 variables were screened by LASSO and logistic regression. Six ML algorithms were constructed and internally validated on a 70%/30% split dataset. Model performance was assessed using multiple metrics, followed by external validation. Interpretability was achieved through SHAP analysis. All six ML algorithms demonstrated strong performance across training, testing, and validation sets. The LightGBM model achieved the best overall performance (AUC = 0.87). Feature importance analysis identified glucose, chronic kidney disease, and hyperlipidemia as the top three most important features for diabetes development in COPD patients. An interpretable ML-based risk prediction model for diabetes in COPD patients was constructed and validated. The LightGBM-based tool shows potential for supporting early personalized care and improving prognosis.

PMID:
42426311
Bibliographic data and abstract were imported from PubMed on 10 Jul 2026.

Read full publication at:
Please sign in to see all details.

Advertisement

Stats

  • Community rating n/a 0 votes
  • Reviewers' rating n/a 0 votes
  • Your rating

1-terrible, 9-excellent. How would you rate this publication? Sign in in to submit your rating.

  • Recommendations n/a n/a positive of 0 vote(s)
  • Views 5
  • Comments 0

Recommended by

  • No recommendations yet.

Post a comment

You need to be signed in to post comments. You can sign in here.

Comments

There are no comments yet.

Advertisement